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Cancer TherapyHydrogel Nanoparticles with Covalently Linked 
Coomassie Blue for Brain Tumor Delineation Visible  
to the Surgeon
Guochao Nie, Hoe Jin Hah, Gwangseong Kim, Yong-Eun Koo Lee, Ming Qin,  
Tanvi S. Ratani, Panagiotis Fotiadis, Amber Miller, Akiko Kochi, Di Gao,  
Thomas Chen, Daniel A. Orringer, Oren Sagher, Martin A. Philbert, and Raoul Kopelman*8
Delineation of tumor margins is a critical and challenging objective during brain 
cancer surgery. A tumor-targeting deep-blue nanoparticle-based visible contrast 
agent is described, which, for the first time, offers in vivo tumor-specific visible color 
staining. This technology thus enables color-guided tumor resection in real time, 
with no need for extra equipment or special lighting conditions. The visual contrast 
agent consists of polyacrylamide nanoparticles covalently linked to Coomassie Blue 
molecules (for nonleachable blue color contrast), which are surface-conjugated 
with polyethylene glycol and F3 peptides for efficient in vivo circulation and tumor 
targeting, respectively.1. Introduction
For many forms of cancer, surgery is an essential treatment 
modality. The precise delineation of tumor margins and sub-
sequent complete surgical resection, without damaging crucial 4 © 2012 Wiley-VCH Vewileyonlinelibrary.com
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[+] These authors contributed equally to this work.structures near the tumor bed, is one of the great challenges in 
brain tumor surgery.[1] The extent of tumor resection relies on 
the precision of tumor delineation and affects the length and 
quality of survival for the cancer patient.[2] In current clini-
cal settings, resection of the tumor is guided by preoperative 
imaging studies, along with the operating surgeon’s ability 
to distinguish the lesion grossly by its appearance and con-
sistency, with respect to normal tissue, which, by itself, is not 
reliable enough to achieve complete resection. In particular, 
brain tumor tissue, which is easily detected radiographically, 
may be virtually indistinguishable from normal brain tissue in 
its visual appearance.
Various attempts for improvement of tumor delinea-
tion during brain tumor surgery have been made, based on 
two types of approaches: 1) implementing medical imaging 
instrumentation, and 2) applying fluorescent or visual con-
trasting reagents. The first approach includes the imple-
mentation of image-guided stereotactic navigation[3] and 
intraoperative magnetic resonance imaging (MRI).[4] These 
high-tech instrumentation-aided techniques have been used 
in the clinic and can greatly improve the accuracy of surgery. 
However, their use still has various restrictions, including 
possible reduced accuracy due to the practicing surgeon’s 
divided attention between patient and monitor, longer setup 
time, high cost, limited availability, as well as poor instrument 
compatibility due to the necessity of having strong magnetic rlag GmbH & Co. KGaA, Weinheim small 2012, 8, No. 6, 884–891
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Figure 1. Significant nonspecific cell staining by dye leaching from 
CB-post-loaded PAA NPs. Brain tumor cells (9L gliosarcoma) incubated 
for 1 h with A) F3-targeted CB-post-loaded PAA NPs and B) nontargeted 
CB-post-loaded PAA NPs exhibit a strong positive blue staining effect 
regardless of cell binding of NPs by F3 targeting.
Scheme 1. Synthesis of CB-APMA: i) POCl3, dimethylformamide (DMF), 
CH2Cl2, 40 °C, 7.5 h/≈20 °C, overnight; ii) APMA, dimethyl sulfoxide 
(DMSO), triethylamine, CH2Cl2, 0 °C, 30 min/≈20 °C, 1.5 h.
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second approach has been attempted by using fluorophores 
or visible dyes to stain tumor tissue. Fluorescein,[5] 5-aminole-
vulinic acid (5-ALA),[6] indocyanine green,[7] bromophenol 
blue,[8] and Coomassie Blue[9] have been suggested. In prin-
ciple, dyes can preferentially stain malignant gliomas as they 
diffuse more readily across the areas of breakdown (fenes-
trations) of the blood–brain barrier. Although this approach 
allows surgeons to fully focus on the patient due to the visual 
contrasting effect coming directly from the tumor tissues, it is 
still subject to several limitations. For instance, fluorescence 
dye-based delineation requires special lighting and the ele-
vated risk in performing operations in near darkness, as well 
as interruptions of surgery. In addition, a general drawback 
of dye-based delineation has been a lack of target specificity, 
systemic cytotoxicity, a requirement of intolerable high doses 
to achieve satisfactory visual contrast, and short-lasting reten-
tion at the desired site.[10]
The use of nanoparticles (NPs) may present a solution 
for overcoming the limitations of the currently proposed 
methods of dye-based tumor delineation, due to their several 
advantages, such as high loading of drugs and contrast agents, 
nontoxicity of the matrix, and selective tumor targeting, 
including passive targeting by the enhanced permeability 
and retention (EPR) effect and active targeting by a surface-
conjugated, tumor-specific targeting moiety.[11] Iron oxide-
based NPs tagged with the near-infrared (NIR) fluorescent 
dye Cy5.5 have been suggested as a method for dye-based 
intraoperative delineation of brain tumors.[12] However, one 
practical flaw of Cy5.5-tagged NPs is that, despite the deep 
tissue penetrating capability of NIR fluorescence, the NIR 
fluorescence of Cy5.5 is invisible to the naked eye and can 
only be visualized on a separate monitor. Our group has pro-
posed an alternative approach, based on the brain-tumor-
targeted delivery of a visual delineating reagent made of 
NPs.[13] We performed a preliminary proof-of-principle study 
on visual tumor delineation by using NP surface-conjugated 
F3 peptides for glioma targeting, with polyacrylamide (PAA) 
NPs containing the blue dye, Coomassie Brilliant Blue G-250 
(CB).[13] CB turned out to be a very good candidate as a vis-
ible color contrast enhancer for intraoperative tumor deline-
ation.[13] It has a vivid blue color in the pH 3 to 11 range, with 
a very high molar extinction coefficient.[14] It is also known to 
be safe for intravenous injection into the human body, even 
at very high doses.[15] However, our approach using the pre-
viously reported CB-loaded NPs still had a significant chal-
lenge with respect to application in vivo. Because the NPs 
were prepared by loading CB into preformed blank NPs by 
“physical” adsorption (termed “post-loading”), they pro-
duced a rather high degree of nonspecific cell staining with 
the passage of time (Figure 1),[10] which may lead to ineffi-
cient specific tumor staining in vivo.
Herein, we report significant improvements made to over-
come the drawbacks of the preliminary approach, including: 
1) development of a covalently linkable CB derivative to pre-
vent unwanted premature dye leaching; 2) modification of the 
NP synthesis procedures to achieve sufficient dye loading by 
covalent linkage, and 3) introduction of polyethylene glycol 
(PEG)-containing crosslinkers for conjugation between © 2012 Wiley-VCH Verlag Gmbsmall 2012, 8, No. 6, 884–891the NP and the F3 peptide, for improved stability in blood 
plasma and for preventing nonspecific binding. The new 
NPs, with covalently loaded CB, showed a highly selective 
blue staining of 9L glioma cells with negligible nonspecific 
staining in vitro, as well as selective tumor staining in vivo, in 
9L-bearing rats with a cranial window, when compared with 
CB-post-loaded PAA NPs. The tumor-specific, nonleachable, 
blue-colored NPs do give good tumor delineation, which can 
be easily visualized by the naked eye, with enough contrast 
to potentially enable complete resection of the tumor with 
no extra equipment, no interruptions, and no unusual lighting 
conditions during surgery.
2. Results and Discussion
2.1. Synthesis of a Crosslinkable CB Derivative  
and its Characterization
As a first step to prepare CB covalently linked PAA NPs, 
commercially available CB was derivatized to an acrylamide-
terminated form, by two-step reaction as summarized in 
Scheme 1. The two sulfonic acid groups were converted into 
sulfonyl chloride groups,[16] forming an intermediate (CB-I), 
and were then changed into sulfamide groups after reacting 
with N-(3-aminopropyl)methacrylamide (APMA) under ba-
sic conditions[17] to make CB-APMA. This modification was 885www.small-journal.comH & Co. KGaA, Weinheim
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performed without separation of CB-I, which is moisture sen-
sitive, but the identity of CB-I was confirmed by mass spec-
trometry showing a molecular ion at m/z 868.1. The color of 
CB and CB-APMA is bright blue, whereas that of CB-I is 
green. The CB-APMA was obtained in a dried powder form, 
with 68% yield, and had 97% purity by elemental analysis 
(C61H74N7O7S2
+(OH−)0.6(SO4
2−)0.2: C 64.04, H 6.58, N 8.58, O 
11.75, S 6.17).
The CB-APMA was characterized by 1H NMR (1D and 
2D), mass, and IR spectrometric measurements. The NMR 
proton assignments for CB-APMA are listed as follows: 1H 
NMR (CD2Cl2, 500 MHz): δ = 7.91–7.69 (m, 4H; Ar−H), 7.47 
(t, J = 7.5 Hz, 2H; CONH), 7.43–7.34 (m, 3H; Ar−H), 7.34–7.26 
(m, 3H; Ar−H), 7.25–7.18 (m, 2H; Ar−H), 7.17–7.10 (m, 2H; 
Ar−H), 7.04 (t, J = 6.5 Hz, 2H; SO2−NH), 6.97–6.74 (m, 4H; 
Ar−H), 6.74–6.44 (m, 4H; Ar−H), 5.87–5.64 (m, 2H; CH2), 
5.31–5.10 (m, 2H; CH2), 4.73(s, 4H; Ar−CH2), 4.02 (q, J = 
7 Hz, 2H; CH3−CH2−O), 3.85–3.49 (m, 4H; CH3−CH2−N), 
3.49–3.41 (m, 4H; CONH−CH2−), 2.99–2.71 (m, 4H; 
SO2NHCH2), 1.94–1.84 (m, 6H; CH3−C), 1.84–1.71 
(br, 6H; CH3−Ar), 1.70–1.54 (m, 4H; CH2CH2CH2), 1.38 
(t, J = 7 Hz, 3H; CH3−CH2−O), 1.30 ppm (t, J = 7 Hz, 6H; 
CH3−CH2−N). The identity of CB-APMA was also confirmed 
by the mass spectrum, which showed a molecular ion at m/z 
1080.50. The IR (KBr) spectra confirmed the presence of 
amide CO at 1654, CO−NH at 1605, CCH at 1494, and 
SO2−NH at 1166 cm−1. (More detailed analysis data are avail-
able in the Supporting Information.)
2.2. Preparation of NPs Containing CB-APMA by Covalent Linkage
CB covalently linked PAA NPs were prepared by reverse 
microemulsion polymerization with monomer mixtures con-
taining CB-APMA, acrylamide (monomer), APMA (comon-
omer), and glycerol dimethacrylate (GDMA, crosslinker; see 
Scheme S1, Supporting Information). CB-encapsulated and 
CB-post-loaded PAA NPs were also prepared for comparison 
(Scheme S1). The crosslinker, GDMA, contains hydrolyzable 
ester bonds, thus making the prepared NPs biodegradable 
in vivo.[11,18] APMA was included for providing the amine 
functionality to the NPs, so the NPs can be modified with F3 
peptides and PEG units (Scheme S2, Supporting Information). 
The CB-APMA is insoluble in water and can also serve as a 
crosslinker as it has two polymerizable carbon double bonds 
(−CC−). The inclusion of CB-APMA was found to greatly 
influence the formation of the NPs. Thus, the synthetic proto-
col for CB-linked PAA NPs had to be significantly modified 
from that of CB-encapsulated or CB-post-loaded PAA NPs. 
The monomers were dissolved in a DMF/water mixture. The 
amount (mole) of GDMA in the monomer mixture was re-
duced by the added amount of CB-APMA, which kept the 
amount of the crosslinkers the same as that used for typical 
PAA NPs. The amount of surfactants was increased by a fac-
tor of ≈3. Compared to preparing blank PAA NPs, about 
16 times higher initiator quantities were required for the initia-
tion of the polymerization, probably because of the significant 
quenching of the produced radicals by the larger amounts of 
dye and surfactant.86 www.small-journal.com © 2012 Wiley-VCH V2.3. Surface Modifications and Cancer-Specific Targeting
To achieve brain-cancer-specific targeted delivery of CB-
loaded PAA NPs, two surface modifications/conjugations 
were made. First, the surface of CB-loaded NPs was PEGylated 
(coated with polyethylene glycol) by using the heterobi-
functional PEG, SCM-PEG-MAL, as a crosslinking reagent 
between the NP and a targeting moiety. Its amine-reactive 
terminal (succinimidyl carboxymethyl ester, SCM) chemically 
links to the primary amine group present on the surface of 
PAA NPs. Then, the sulfhydryl-reactive terminal (maleimidyl 
ester, MAL) binds to the sulfhydryl group in F3-Cys peptide 
for cancer targeting or to l-cysteine for control (Scheme S2). 
The surface charge in each modification step was measured as 
an indicator showing whether the product was formed as de-
sired, using the dynamic light scattering (DLS) zeta potential 
measurement technique. Unmodified NPs exhibit a relatively 
strong positive charge (+17.38 ± 3.30 mV in zeta potential) due 
to the presence of protonated amine groups (-NH3
+) on the 
surface. PEGylation on the surface resulted in a significantly 
reduced positive charge (+2.98 ± 1.40 mV). The coverage of 
PAA NPs by PEG was estimated to be about 40 PEG mol-
ecules per single PAA NP by UV/Vis absorption-based analy-
sis done after treating the NPs with fluorescein-labeled PEG-
succinimidyl ester. F3-conjugated NPs regained a net positive 
surface charge (+15.11 ± 2.36 mV) because of the strong basic 
amino acid composition of the F3 peptide.
The introduction of PEG in between the NP and the F3 
peptide was another effort to improve in vivo tumor delinea-
tion efficacy, compared to the previous approach that utilized 
a relatively small molecular crosslinker, sulfo-SMCC.[13] 
Surface PEGylation can effectively suppress the nonspecific 
binding by the free motion of the electrically neutral, long 
polymer PEG chains, thereby allowing only target-specific 
binding to the cancer cells by the F3 peptide. Also, PEGyla-
tion can improve the colloidal stability (suspendability) of the 
NPs in physiological media, which results in longer plasma 
circulation times. Such effects should improve the in vivo 
function of the F3-targeted CB-linked PAA NPs.
2.4. NP Characterization
The scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM) images show that the CB-linked 
NPs have spherical particulate morphology and a size of ≈45 nm 
in diameter, whereas the CB-encapsulated or CB-post-load-
ed NPs have a size of ≈30 nm (Figure 2). The average sizes 
(diameters) of CB-linked PAA NPs, CB-encapsulated PAA 
NPs, and CB-post-loaded PAA NPs in water, measured by 
DLS, are (86.8 ± 21.0), (57.3 ± 11.8) and (54.1 ± 10.2) nm, re-
spectively, whereas for blank PAA NPs it is 53.4 ± 9.5 nm. The 
fact that the hydrodynamic sizes of these NPs are much larger 
than those determined by the electron micrographs indicates 
that the PAA NPs can swell in aqueous solution, manifesting 
a hydrogel characteristic. The average sizes of the F3-targeted 
and nontargeted (PEGylated) CB-linked PAA NPs are, 
respectively, (90.3 ± 7.1) and (88.6 ± 11.9) nm by DLS, which 
indicates that surface conjugation does not affect the particle erlag GmbH & Co. KGaA, Weinheim small 2012, 8, No. 6, 884–891
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Figure 2. SEM and TEM images of the prepared NPs: A) CB covalently 
linked PAA NPs; B) CB-encapsulated PAA NPs; and C) CB-post-loaded 
PAA NPs.size significantly. The size of all CB-loaded PAA NPs, before 
and after surface modification, falls into the range of 10–100 nm, 
which is generally the accepted optimal size range for in vivo 
applications, because a particle in this range is too large to 
undergo renal elimination and too small to be recognized by 
phagocytes.[19–21]
We also confirmed that various dye loading methods 
(post-loading and covalent linking) did not make recogniz-
able differences in the zeta potential value. The amount of 
conjugated F3 peptide was determined to be 0.027 μmol mg−1  
of NP by weight, by quantitative amino acid assays. We 
believe that F3 peptides are conjugated mostly to the surface 
through PEG crosslinker because of: 1) PEG molecules being 
mostly located on the surface, as shown by the significant sur-
face charge reduction after PEGylation and the regaining of 
positive surface charge after F3 conjugation (Section 2.3); and 
2) considering the relatively large molecular weight of the F3 
peptide (3566 g mol−1). Our previous studies show that mol-
ecules having molecular weights larger than ≈2500 Da do not 
leach out of PAA NPs, thus indicating that such molecules 
can hardly enter into the NPs from the outside.[22]
2.5. Quantification of Dye Loading Efficiency
The absorption spectra of CB-linked NPs in aqueous solution 
show that their absorption maximum is observed at 610 nm 
while that of CB-free dye in aqueous solution is at 597 nm 
(Supporting Information). Just as for the solvent-dependent © 2012 Wiley-VCH Verlag Gmsmall 2012, 8, No. 6, 884–891spectral shifts of the dyes,[23] such a peak shift may be due 
to a polarity and polarizability of the CB-linked NP matrix 
that differs from that of water or that of the normal PAA NP 
matrix. CB has a peak at 618 nm when dissolved in DMF. The 
observed peak shift does not produce significant visible color 
changes (Supporting Information).
The loading of CB per NP is an important factor for suc-
cessful visible color-based tumor delineation. In our studies 
with CB-free dye, the estimated dose for obtaining a suf-
ficient color delineation effect in a rat brain tumor window 
(BTW) model was about 70 mg kg−1, although the color con-
trast started to fade at about 60 min after injection.[9] The 
required CB dose for the CB-loaded NPs may be lower than 
the CB-free dye dose, through the expected enhancement in 
effectivity due to passive delivery by the EPR effect, the 
surface-conjugated PEG, and the tumor-specific targeting 
moieties. We aimed at using half of the free CB dose, that is, 
35 mg kg−1, for CB-loaded NPs. According to our previous 
in vivo animal studies, the PAA NPs showed no evidence of 
alterations in histopathology or clinical chemistry values at 
doses of 10 mg kg−1 to 1 g kg−1.[11] We chose the maximum 
NP dose to be equal to or less than 500 mg kg−1. To match 
the dose requirement for the CB dye and the NPs, the CB 
loading per NP should be at least ≈7 wt%. Among the three 
types of CB-loaded PAA NPs, the CB-encapsulated PAA 
NPs showed the worst CB loading efficiency, achieving only 
about 0.5 wt% loading of CB per NP, at most, and this sample 
was excluded from further studies. The CB-post-loaded PAA 
NPs were obtained with high dye contents (up to 9%), with 
>90% of loading efficiency, which were controlled by the 
input amount of CB. The CB loading efficiency within CB-
linked NPs was also high (ca. 70%) and controlled by the 
input amount of CB-APMA. A CB loading of up to 14 wt% 
was achieved for the CB-linked NPs.
2.6. Dye Leaching under Simulated Physiological Conditions
Dye leaching tests were performed for the CB covalently 
linked PAA NPs and the CB-post-loaded PAA NPs after be-
ing incubated in a pH 7.4 phosphate-buffered saline (PBS) 
solution containing 9% bovine serum albumin (BSA) at 
37 °C (mimicking the composition of a physiological fluid) for 
2 h and by measuring the CB content in the filtrate separated 
from the NPs by centrifugal filtration. There was significant 
leaching of CB out of the CB-post-loaded PAA NPs (60 ± 
9%), but no detectable leaching of CB out of the CB-linked 
NPs. The high dye leaching out of the CB-post-loaded NPs 
may be attributed to the dye loading being achieved by physi-
cal interactions, namely electrostatic or hydrophobic interac-
tions, between the dye and the NPs. The latter are thus easily 
affected by the surrounding environment, which can render 
even stronger interactions. This characteristic represents a 
crucial drawback of the post-loaded dye NPs when the aim 
is in vivo tumor delineation. As shown by the above results, 
the covalent linkage of the CB molecule to the NP matrix 
polymer backbone completely eliminates dye leaching, so 
that the entire dye content can be delivered to the tumor with 
the targeted NPs.887www.small-journal.combH & Co. KGaA, Weinheim
G. Nie et al.
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Figure 3. Examination of cytotoxicity of CB-loaded PAA NPs. Compared to 
the cell-only control, none of the three kinds of NPs, CB-post-loaded NPs 
(CB-PL), CB-linked NPs (CB-C), and blank PAA NPs, showed a statistically 
meaningful reduction in the cell survival rate, thus indicating negligible 
cytotoxicity. Dye loading differences (7 and 4.5%) also showed only 
negligible differences in cell viability.
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4.5 % dye loading2.7. Cytotoxicity Examination by MTT Assay
The potential toxicity of the CB-loaded NPs was tested by an 
MTT assay. As displayed in Figure 3, cell survival rates did not 
show noticeable differences among CB-post-loaded NPs, CB 
covalently linked NPs, blank NPs, and the control (cells only). 
The average cell survival rates were higher than 96% in all 
cases, regardless of the NP type and dye content. This result 
clearly shows that the PAA NP matrix, with or without CB 
dye loading, does not cause significant cytotoxic effects and 
thus may be readily deployed for intraoperative in vivo 
applications.
2.8. In vitro Cell Staining
Based on the effective suppression of dye leaching, we per-
formed in vitro cell staining experiments on 9L gliosarcoma 
cells, using F3-conjugated or nontargeted PAA NPs (PEGylat-
ed control NPs) containing 7 wt% CB by covalent linking, as 
previously described.[13] While F3-conjugated CB-linked NPs 
could effectively stain the 9L cell pellet to a noticeable blue 
color, under identical conditions the nontargeted counter-
parts induced a negligible blue staining effect (Figure 4). Note 
that in the case of CB-post-loaded NPs, even the nontargeted 
ones caused significant tumor cell staining (Figure 1).[13] This 
suggests that the amount of CB dye that remained within the 8 www.small-journal.com © 2012 Wiley-VCH V
Figure 4. In vitro cell staining by A) F3-targeted CB-linked NPs, B) nontarg
after 1 h of incubation, and C) comparison of blue staining by saturatio
F3-targeted CB-linked NPs caused a clear blue staining effect whereas the 
caused a negligible effect.CB-post-loaded NPs may decrease significantly by the leach-
ing out of dye molecules when the NPs reach the tumor, and 
that the leached-out free dye may cause nonspecific staining 
of other tissues, thus limiting their use in vivo. Meanwhile, the 
CB-linked NPs, which showed no premature dye leaching, are 
expected to provide stronger and longer-lasting tumor deline-
ations in vivo.
2.9. In vivo Tumor Delineation
Based on the aforementioned improvements, an in vivo tumor 
delineation study was performed in a rat BTW model,[9] that 
is, rats with implanted 9L gliosarcoma and with a glass cranial 
window, so that the in vivo tumor delineation could be evalu-
ated in real time by visual observation through the window, as 
previously described.[9] Figure 5 shows representative pictures 
of the tumors in the BTW models at 0, 60, and 120 min after 
injection of the three kinds of 7 wt% CB-loaded NPs—F3- 
targeted and nontargeted CB-linked PAA NPs, and nontargeted 
CB-post-loaded PAA NPs—at an NP dose of 500 mg kg−1. The 
tumor margin that was poorly defined before administration of 
the NPs becomes readily apparent after administration of any 
of the three CB-loaded NPs. As shown in Figure 5, the relative 
strengths of visual delineation induced by the NPs were in the 
order: F3-targeted CB-linked NPs > nontargeted CB-linked 
NPs > nontargeted CB-post-loaded NPs. The reason that non-
targeted NPs exhibited tumor-specific accumulation, though 
to a weaker extent, can be explained as being a consequence 
of passive targeting by the EPR effect. In spite of the same dye 
content (7%), the nontargeted CB-post-loaded NPs showed a 
significantly reduced delineation effect compared to the non-
targeted CB-linked NPs. This reduction is attributed to the loss 
of CB content in the post-loaded NPs, due to dye leaching; this 
is borne out by the decreasing contrast with time (Figure 5). 
The F3-targeted, CB-linked NPs showed the strongest tumor 
delineation effect of all the samples, and this enhancement is 
attributed to the additive effects of 1) active targeting by the 
F3 peptide, 2) passive targeting by the EPR effect, and 3) no 
loss of dye content. These results clearly manifest the advan-
tage of F3-targeted CB-linked NPs for tumor-selective deline-
ation. Also, the progress of tumor delineation contrast over 
time reveals further evidence of the improvement due to the 
covalent attachment of the CB dye to the NP matrix. The color 
of the tumors treated by both F3-targeted and nontargeted 
CB-linked NPs became stronger with time (up to 120 min). 
However, the tumor staining by the nontargeted CB-post-erlag GmbH & Co. KGaA, 
eted CB-linked NPs 
n analysis.[9,13] The 
nontargeted control loaded NPs started to fade after 60 min. In 
our previous study with free CB dye, we 
also observed such early clearance of the 
color from the tumor.[9] This again indi-
cates that the CB may keep leaching out of 
the CB-post-loaded NPs, thus resulting in 
less efficient tumor delineation. Currently, 
kinetics and dose-dependency studies with 
F3-targeted and nontargeted CB-linked 
NPs are ongoing, to evaluate the optimal 
doses of NPs and CB as well as the efficien-
cy of the F3 targeting over time.Weinheim small 2012, 8, No. 6, 884–891
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Figure 5. Left: Photographs of representative tumors in BTW models, at 0, 60, and 120 min after administration of A) F3-targeted CB-linked NPs, 
B) nontargeted CB-linked NPs, and C) nontargeted CB-post-loaded NPs. The tumor margin in each animal was marked by a white dashed line on the 
initial (0 min) images. The F3-targeted CB-linked NPs (A) localize within the tumor, thus enabling an obvious visual delineation from the surrounding 
normal brain, whereas nontargeted control (B) and nontargeted CB-post-loaded control NPs (C) result in a noticeably inferior delineation effect. 
This degree of delineation would improve the ability of surgeons to distinguish tumor from normal brain under standard lighting conditions. Right: 
Colorimetric analysis results with ImageJ software,[9,13] to quantify the degree of color change in the tumor. The difference in red hue is the best 
method to reflect the visual difference between tumor and normal brain.3. Conclusion
We have demonstrated the preparation of tumor-targeted, in-
tensely blue colored NP agents for tumor-specific visible color 
contrast, designed to aid in intraoperative tumor margin delin-
eation. The color contrast agent is made of PAA hydrogel NPs 
that are covalently linked with CB dye, by copolymerizing the 
CB-linked acrylamide (CB-APMA) that was synthesized for 
this purpose. The CB covalently linked PAA NPs have the ad-
vantages of 1) good suspension capability in aqueous solutions 
and 2) no leaching of the color contrast ingredient. These NP 
agents, through the attachment of PEG and F3 peptide, en-
able efficient and lasting in vivo tumor targeting by the dye. 
The selective and visible tumor staining ability was confirmed 
both in cells (in vitro) and in a 9L tumor-bearing rat model (in 
vivo). The tumor-targeting blue colored NP agents are likely 
to enable color-guided tumor resection in real time, without 
the need for extra equipment, special lighting conditions, or 
surgery interruptions.
4. Experimental Section
Materials: Coomassie Blue G (CB), triethylamine (TEA), dichlo-
romethane, acrylamide (AA), glycerol dimethacrylate (GDMA), 
ammonium persulfate (APS), N,N,N′,N′-tetramethylethylenediamine 
(TEMED), sodium dioctyl sulfosuccinate (AOT), Brij 30, hexane, N,N-
dimethylformamide (DMF), dimethyl sulfoxide (DMSO), l-cysteine, 
Dulbecco’s modified Eagle’s medium (DMEM), Rosewell Park 
Memorial Institute medium (RPMI-1640), and 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased 
from Sigma Aldrich. Phosphorus oxychloride, petroleum ether 
(40 to 60 °C), and toluene were purchased from Acros Organics. 
N-(3-Aminopropyl)methacrylamide hydrochloride (APMA) was 
purchased from Polysciences Inc. Ethanol (95%), anhydrous 
ethyl ether, and hexane were purchased from Fisher Scientific. 
Anthracene-9,10-dipropionic acid, disodium salt (ADPA) was pur-
chased from Molecular Probes. Fluorescein isothiocyanate (FITC) 
was purchased from Thermo Scientific. Bovine serum albumin 
(BSA, 30%) was purchased from United States Biological Corpora-
tion. Phosphate-buffered saline (PBS) solution (pH 7.4) was made 
with phosphate-buffered saline tablet from Sigma Aldrich. F3-Cys © 2012 Wiley-VCH Verlag Gmbsmall 2012, 8, No. 6, 884–891peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) was purchased 
from SynBioSci. A heterobifunctional polyethylene glycol (MAL-
PEG-NHS, 2k) was purchased from Creative PEGWorks. Six-well 
cell culture plates and 96-well microplates were purchased from 
BD Biosciences. The water used throughout the experiments 
was deionized (DI) water, purified by a Milli-Q system from 
Millipore Co.
Synthesis of CB-APMA: CB (8.54 g, 90% purity commercial CB) 
was added to a 500 mL dry round-bottom flask containing DMF 
(70 mL). After sonication, dichloromethane (200 mL) was added to 
the dye solution followed by phosphorus oxychloride (32 mmol). 
The mixture was refluxed for 7.5 h at ≈40 °C and then cooled to 
room temperature overnight. The reaction mixture was cooled in 
an ice water bath, filtered into a suction flask containing APMA 
(25 mmol) in DMSO (10 mL), dichloromethane (50 mL), and TEA 
(153 mmol) in an ice water bath, and then stirred for 1.5 h at room 
temperature. Petroleum ether (500 mL) was added to the suction 
flask to precipitate the blue dye. The oily dye residue was dis-
solved in dichloromethane (200 mL), and toluene (500 mL) was 
added to precipitate the blue dye. The precipitate was filtered 
under vacuum, and then washed with ethyl ether to obtain a dry 
powder. Abundant DI water was added to wash the dry product to 
eliminate the water-soluble impurities. After vacuum drying, the 
product was dissolved in dichloromethane (200 mL) in a beaker 
and the mixture was stirred. DI water (200 mL) and subsequently 
ethyl ether (280 mL) were added to the mixture with stirring for 
≈10 min and then the solution was allowed to stand for 2–8 h. 
The solvents were decanted, vacuum filtered, then the product 
was dried in a vacuum oven. The product was recrystallized from 
dichloromethane. An iridescent red-violet crystalline powder 
(6.8 g), CB-APMA hydroxide (see Scheme 1), was obtained with 
68% yield and 97% purity.
Preparation of CB-Loaded NPs: CB Covalently Linked PAA NPs: 
CB covalently linked PAA NPs were prepared by a reverse micro-
emulsion polymerization method. A monomer solution was pre-
pared by dissolving acrylamide (610 mg) and APMA (45 mg) in 
water (1 mL). A dye solution was prepared by dissolving CB-APMA 
(100 mg) in DMF (0.4 mL) and then GDMA (360 μL) was added 
to the dye solution. The monomer solution was added to the 
mixture and then it was stirred and sonicated to make a homo-
geneous solution. The prepared CB-containing monomer solution 889www.small-journal.comH & Co. KGaA, Weinheim
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was added to deoxygenated hexane (120 mL) that contained two 
surfactants, AOT (3.9 g) and Brij 30 (10.3 mL). After stirring the 
mixture under an inert atmosphere for 20 min, a freshly prepared 
50% (w/v) APS solution (240 μL) and TEMED (150 μL) were added 
to initiate polymerization. The solution was then stirred under an 
inert atmosphere at room temperature for 1 h. After completion of 
the polymerization, hexane was removed with a rotary evaporator 
and the residue was made into a suspension by adding ethanol. 
The suspension was subjected to a washing procedure in an 
Amicon filtration system (Millipore Co.) with a 500 kDa filter mem-
brane under 10–20 psi of pressure. The washing procedure was 
carried out with ethanol ten times and with water ten times, during 
which surfactants and unreacted molecules were removed from 
the product. The resultant CB covalently linked NPs were obtained 
through a freeze-drying process.
Preparation of CB-Loaded NPs: CB-Encapsulated PAA NPs: 
CB-encapsulated PAA NPs were prepared by a reverse microemul-
sion polymerization method. A CB-containing monomer solution 
was prepared by dissolving acrylamide (711 mg), APMA (55 mg), 
and CB (100 mg) in water (1.4 mL). GDMA (470 μL) was added to 
the mixture and then it was stirred and sonicated to make a homo-
geneous solution. The mixture solution was added to deoxygenated 
hexane (120 mL) that contained two surfactants, AOT (3.9 g) and 
Brij 30 (10.3 mL). After stirring the mixture under an inert atmos-
phere for 20 min, a freshly prepared 50% (w/v) APS solution 
(240 μL) and TEMED (150 μL) were added to initiate polymeriza-
tion. The solution was then stirred under an inert atmosphere at 
room temperature for 1 h. After completion of the polymerization, 
hexane was removed with a rotary evaporator and the residue was 
made into a suspension by adding ethanol. The suspension was 
subjected to a washing procedure in an Amicon filtration system 
(Millipore Co.) with a 500 kDa filter membrane under 10–20 psi of 
pressure. The washing procedure was carried out with ethanol ten 
times and with water ten times, during which surfactants and unre-
acted molecules were removed from the product. The resultant CB-
encapsulated NPs were obtained through a freeze-drying process.
Preparation of CB-Loaded NPs: CB-Post-Loaded PAA NPs: For 
the post-loading of CB, blank PAA NPs were prepared by a reverse 
microemulsion polymerization method. A monomer solution was 
prepared by dissolving acrylamide (711 mg) and APMA (55 mg) in 
water (1.3 mL). GDMA (470 μL) was added to the monomer solu-
tion and then the mixture was stirred and sonicated to make a 
homogeneous solution. The mixture solution was added to deox-
ygenated hexane (45 mL) that contained two surfactants, AOT 
(1.6 g) and Brij 30 (3.3 mL). After stirring the mixture under an inert 
atmosphere for 20 min, a freshly prepared 10% (w/v) APS solution 
(100 μL) and TEMED (100 μL) were added to initiate polymeriza-
tion. The solution was then stirred under an inert atmosphere at 
room temperature for 2 h. After completion of the polymerization, 
hexane was removed with a rotary evaporator and the residue was 
made into a suspension by adding ethanol. The suspension was 
subjected to a washing procedure in an Amicon filtration system 
(Millipore) with a 300 kDa filter membrane under 10–20 psi of 
pressure. The washing procedure was carried out with ethanol ten 
times and with water ten times, during which surfactants and unre-
acted molecules were removed from the product. The resultant 
blank PAA NPs were obtained through a freeze-drying process.
The blank PAA NPs (50 mg) prepared were dispersed in water 
(5 mL). CB aqueous solution (1 mL, 5 mg mL−1) was added under 0 www.small-journal.com © 2012 Wiley-VCH Vstirring and the mixture was stirred for 2 h at room temperature. 
With an Amicon centrifugal filter (Millipore, 100 kDa), a rinsing 
procedure was carried out by centrifugation at 5000 g for 20 min. 
During washing, the unloaded dye in the mixture solution was 
removed through a membrane. This procedure was repeated five 
times. The CB-post-loaded PAA solution was collected with a con-
centration of 20 mg mL−1.
Preparation of F3-Targeted CB-Loaded PAA NPs: CB covalently 
linked PAA NPs (50 mg) or CB-post-loaded PAA NPs were dissolved 
in PBS (2.5 mL, pH 7.4). NHS-PEG-MAL (4 mg), a bifunctional con-
jugating polyethylene glycol, was added to the NP solution and the 
mixture was stirred for 30 min. With an Amicon centrifugal filter 
(Millipore, 100 kDa), a rinsing procedure was carried out by cen-
trifugation at 5000 g for 20 min. During washing, unreacted mol-
ecules in the mixture solution were removed through a membrane. 
This procedure was repeated three times. The NP solution was 
reconstituted in PBS to 20 mg mL−1, and F3-Cys peptide (2 μmol) 
was added. The mixture was stirred overnight at room tempera-
ture. l-Cysteine aqueous solution (63 μL, 10 mg mL−1) was added 
and the mixture was stirred for 2 h to deactivate the functional 
ends of PEG unreacted with the peptides. The resultant F3-targeted 
CB-loaded PAA NPs were obtained after additional washing with 
repetitive centrifugation.
Preparation of Nontargeted CB-Loaded PAA NPs: CB covalently 
linked PAA NPs (50 mg) or CB-post-loaded PAA NPs were dissolved 
in PBS (2.5 mL, pH 7.4). NHS-PEG-MAL (4 mg), a bifunctional con-
jugating polyethylene glycol, was added to the NP solution and the 
mixture was stirred for 30 min. With an Amicon centrifugal filter 
(Millipore, 100 kDa), a rinsing procedure was carried out by cen-
trifugation at 5000 g for 20 min. During washing, unreacted mol-
ecules in the mixture solution were removed through a membrane. 
This procedure was repeated three times. The NP solution was 
collected with a concentration of 20 mg mL−1. l-Cysteine aqueous 
solution (125 μL, 10 mg mL−1) was added and the mixture was 
stirred for 2 h. The resultant nontargeted CB-loaded PAA NPs were 
obtained after additional washing with repetitive centrifugation.
Dye Leaching Tests: CB-loaded PAA NPs (10 mg), CB covalently 
linked or CB-post-loaded, were dissolved in PBS (1.4 mL, pH 7.4). 
A BSA solution (0.6 mL, 30%) was added to the NP solution and 
the mixture was stirred for 2 h at 37 °C. The mixture was diluted 
by adding PBS (6 mL, pH 7.4) and filtered in an Amicon filtration 
system (Millipore) with a 500 kDa filter membrane under 10–20 psi 
of pressure. The first filtrate was collected with a volume of 5 mL 
and then PBS (6 mL, pH 7.4) was added to the Amicon container 
for the second filtration. Repeatedly, three filtrates were obtained 
with a volume of 5 mL. The filtrates were checked for their absorp-
tion with a UV/Vis spectrometer to characterize the dye leaching 
from the NPs.
Cell Culture: The human breast adenocarcinoma cell line MCF-7 
and rat gliosarcoma cell line 9L were cultivated in RPMI-1640 with 
heat-inactivated fetal bovine serum (10%). The cells were plated 
on the glass coverslips in six-well plates for confocal microscopy 
imaging and 96-well plates for MTT cell viability assay.
MTT Cell Viability Assay: The cytotoxicity induced by the PAA NP 
matrix with various CB loadings—CB-post-loaded (7 and 4.5 wt% 
dye content), CB covalently linked (7 and 4.5 wt% dye content), 
or without CB (blank)—as well as cells without NPs (control), was 
evaluated by MTT cell viability assay that examines metabolic 
activity. 9L cells were plated on a 96-well plate with cell density erlag GmbH & Co. KGaA, Weinheim small 2012, 8, No. 6, 884–891
Hydrogel Nanoparticles with Covalently Linked Coomassie Blueof 5000 cells well−1 and cultivated overnight. Each type of NP was 
added to the wells (at 1 mg mL−1) and incubated with the cells for 
1 h. The cell medium was carefully replaced with MTT-containing 
medium (0.5 mg mL−1) and cells were further incubated for 4 h. 
Then, the cell medium was aspirated gently and DMSO (200 μL) 
was added to each well to solubilize the formazan crystals pro-
duced from MTT in viable cells. After overnight rocking of the plate, 
the visible absorption at a wavelength of 550 nm of each well was 
measured with a Molecular Devices Spectramax Plus 384 plate 
reader. Results from 12 wells for each NP matrix were averaged.
In vitro Cell Staining by Visible Colorimetry: Four kinds of CB-
loaded NPs containing an equal amount of CB were prepared for 
the tests: F3-targeted CB-linked PAA NPs, nontargeted CB-linked 
PAA NPs, F3-targeted CB-post-loaded NPs, and nontargeted CB-
post-loaded NPs. 9L cells were cultivated for several days until they 
reached sufficient confluency. The cells were lifted off the bottom 
of a Petri dish by trypsinization and centrifuged to obtain a cell 
pellet (2000 rpm for 5 min). The supernatant was removed from 
the centrifuge tube to get rid of the trypsin and the cell pellet was 
resuspended in fresh colorless RPMI-1640 medium. The number 
of cells was counted with a hemacytometer and four centrifuge 
tubes containing cell suspensions of 5 × 106 cells were prepared. 
The cell suspension was incubated with each NP at 0.5 mg mL−1 
for 1 h. Then, the cell suspension was centrifuged to obtain a cell 
pellet (2000 rpm for 5 min) to remove unbound NPs. The superna-
tant was taken from each tube carefully, so as not to disturb the 
pellet. A picture of each cell pellet was taken with a digital camera 
to show the degree of blue staining.
In vivo Tumor Delineation Study: The in vivo tumor delineation 
was performed in a rat brain tumor model that was prepared as 
previously described.[8] Briefly, biparietal craniectomies were per-
formed on 8-week-old Sprague–Dawley rats. 9L glioma cells were 
injected intraparenchymally. A coverslip was bonded to the cranial 
defect with cyanoacrylate glue. When the tumor radius reached 
1–2 mm, CB-loaded NPs were administered intravenously while 
the appearance of the cortical surface was recorded.
Supporting Information
Supporting Information is available from the Wiley Online Library 
or from the author. It includes detailed experimental procedures 
and analyses; NMR (CB, CB-APMA), IR (CB-APMA), mass spectra 
(CB, CB-I, CB-APMA), and elemental analysis (CB-APMA); absorp-
tion spectra of CB and CB-linked PAA NPs; and schemes for NP 
preparation and surface targeting.
Acknowledgements 
This work was supported by Grants R33CA125297-R33CA125297-
03s1, R01 EB007977, and R01 EB007977-02s1 (RK) and Guangxi 
Education Department (201102ZD031, GN).© 2012 Wiley-VCH Verlag Gmbsmall 2012, 8, No. 6, 884–891 [1] L. Rogers, J. Pueschel, R. Spetzler, W. Shapiro, S. Coons, 
T. Thomas, B. Speiser, J. Neurosurg. 2005, 102, 629–636.
 [2] a) N. Sanai, M. S. Berger, Neurosurgery 2008, 62, 753–
764; b) S. S. Lo, K. H. Cho, W. A. Hall, W. L. Hernandez, 
R. J. Kossow, C. K. Lee, H. B. Clark, Int. J. Cancer 2001, 96, 71–78; 
c) G. J. LaValle, D. A. Martinez, D. Sobel, B. DeYoung, E. W. Martin, 
Surgery 1997, 122, 867–871.
 [3] P. W. A. Willems, M. J. B. Taphoorn, H. Burger, J. W. B. van der 
Sprenkel, C. A. Tulleken, J. Neurosurg. 2006, 104, 360–368.
 [4] C. Nimsky, O. Ganslandt, H. Kober, M. Buchfelder, R. Fahlbusch, 
Neurosurgery 2001 , 48, 1082–1089.
 [5] J. Shinoda, H. Yano, S. I. Yoshimura, A. Okumura, Y. Kaku, 
T. Iwama, N. Sakai, J. Neurosurg. 2003, 99, 597–603.
 [6] a) W. Stummer, S. Stocker, S. Wagner, H. Stepp, C. Fritsch, 
C. Goetz, A. E. Goetz, R. Kiefmann, H. J. Reulen, Neurosurgery 
1998, 42, 518–525; b) W. Stummer, A. Novotny, H. Stepp, 
C. Goetz, K. Bise, H. J. Reulen, J. Neurosurg. 2000, 93, 
1003–1013.
 [7] G. W. Britz, S. Ghatan, A. M. Spence, M. S. Berger, J. Neuro-Oncol. 
2002, 56, 227–232.
 [8] T. Ozawa, G. W. Britz, D. H. Kinder, A. M. Spence, S. VandenBerg, 
K. R. Lamborn, D. F. Deen, M. S. Berger, Neurosurgery 2005, 57, 
1041–1046.
 [9] D. A. Orringer, T. Chen, D. L. Huang, W. M. Armstead, B. A. Hoff, 
Y. E. L. Koo, R. F. Keep, M. A. Philbert, R. Kopelman, O. Sagher, 
Neurosurgery 2010, 66, 736–743.
[10] D. A. Hansen, A. M. Spence, T. Carski, M. S. Berger, Surg. Neurol. 
1993, 40, 451–456.
[11] Y. E. L. Koo, G. R. Reddy, M. Bhojani, R. Schneider, M. A. Philbert, 
A. Rehemtulla, B. D. Ross, R. Kopelman, Adv. Drug Delivery Rev. 
2006, 58, 1556–1577.
[12] a) O. Veiseh, C. Sun, C. Fang, N. Bhattarai, J. Gunn, F. Kievit, K. Du, 
B. Pullar, D. Lee, R. G. Ellenbogen, J. Olson, M. Zhang, Cancer Res. 
2009, 69, 6200–6207; b) O. Veiseh, C. Sun, J. Gunn, N. Kohler, 
P. Gabikian, D. Lee, N. Bhattarai, R. Ellenbogen, R. Sze, 
A. Hallahan, J. Olson, M. Zhang, Nano Lett. 2005, 5, 1003–
1008; c) M. Kircher, U. Mahmood, R. S. King, R. Weissleder, 
L. Josephson, Cancer Res. 2003, 63, 8122–8125.
[13] D. A. Orringer, Y. E. L. Koo, T. Chen, G. Kim, H. J. Hah, H. Xu, 
S. Wang, R. Keep, M. A. Philbert, R. Kopelman, O. Sagher, Neuro-
surgery 2009, 64, 965–971.
[14] H. J. Chial, H. B. Thompson, A. G. Splittgerber, Anal. Biochem. 
1993, 209, 258–266.
[15] S. H. Taylor, J. P. Shillingford, Brit. Heart J. 1959, 31, 497–504.
[16] S. Fujita, Synthesis 1982, 423–424.
[17] S. G. Jarboe, M. S. Terrazas, P. Beak, J. Org. Chem. 2008, 73, 
9627–9632.
[18] S. J. Holland, B. J. Tighe, P. L. Gould, J. Controlled Release 1986, 4, 
155–180.
[19] S. M. Moghimi, A. C. Hunter, J. C. Murray, Pharmacol. Rev. 2001, 
52, 283–318.
[20] S. M. Moghimi, B. Bonnemain, Adv. Drug Delivery Rev. 1999, 37, 
295–312.
[21] R. Weissleder, J. F. Heautot, B. K. Schaffer, N. Nossiff, M. I. Papisov, 
A. A. Bogdanov, T. J. Brady, Radiology 1994, 191, 225–230.
[22] Y. Koo Lee, E. E. Ulbrich, G. Kim, H. Hah, C. Strollo, W. Fan, 
R. Gurjar, S. M. Koo, R. Kopelman, Anal. Chem. 2010, 82, 
8446–8455.
[23] C. Reichardt, in Solvents and Solvent Effects in Organic Chemistry, 
2nd ed., VCH, Weinheim 1988.
Received: August 8, 2011 
Revised: November 11, 2011 
Published online: January 9, 2012891www.small-journal.comH & Co. KGaA, Weinheim
